Effects of sacubitril/valsartan versus valsartan on renal function in patients with and without diabetes and heart failure with preserved ejection fraction: insights from PARAGON‐HF

Figures

• 

  Figure 1. Change in estimated glomerular filtration rate (eGFR) over time in patients with and without diabetes. Adjusted means for eGFR over a period of 192 weeks were obtained from repeated‐measures mixed‐effect models. Error bars indicate 95% confidence intervals. eGFR was calculated according to the Chronic Kidney Disease Epidemiology Collaboration equation. Numbers of available measurements at each time point per arm are displayed below. *P‐values are reported for differences in eGFR change between patients treated with valsartan (V) and patients treated with sacubitril/valsartan (S/V). DM, diabetes mellitus.

• 

  Figure 2. Kaplan–Meier analysis of the renal composite outcome by diabetes status. Estimates of the probability of a first occurrence of the renal composite outcome (estimated glomerular filtration rate reduction of ≥50% relative to baseline, development of end‐stage renal disease, or death attributable to renal causes) obtained from Kaplan–Meier failure analyses. CI, confidence interval; HR, hazard ratio.

• 

  Figure 3. Treatment effect of sacubitril/valsartan, compared with valsartan, on the renal composite outcome (estimated glomerular filtration rate reduction of ≥50% relative to baseline, development of end‐stage renal disease, or death attributable to renal causes) across a range of baseline glycated haemoglobin (HbA1c). Estimated rate ratios and 95% confidence intervals were obtained from negative binomial regression models with HbA1c expressed via restricted cubic spline.

• 

  Figure 4. Treatment effect of sacubitril/valsartan, compared with valsartan, on the renal composite outcome (estimated glomerular filtration rate reduction [eGFR] of ≥50% relative to baseline, development of end‐stage renal disease, or death attributable to renal causes) across a range of baseline eGFR. Estimated rate ratios and 95% confidence intervals were obtained from negative binomial regression models with baseline eGFR expressed via restricted cubic spline.